Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Phase 4

• Conditions: Smoking; Acute Coronary Syndrome
• Interventions: Drug: control; Drug: Varenicline 100 mg by mouth twice daily

• Registration Number: NCT01170338
• Lead Sponsor: Newark Beth Israel Medical Center

Brief Summary

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Status Verified: 2010-07
• Study First Submitted: 2010-07-26
• Study First Submitted QC: 2010-07-26
• Last Update Submitted: 2010-07-26
• Study First Posted: 2010-07-27
• Last Update Posted: 2010-07-27
• Primary Completion: 2011-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• active smokers presenting to hospital with an acute coronary syndrome

Exclusion Criteria

• patients with an acute coronary syndrome who are not active smokers

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
sugar pill	control	-
active Chantix	Varenicline 100 mg by mouth twice daily	active drug to help smoking cessation

Primary Outcome Measures

Name	Time	Method
nicotine levels	1 month

Secondary Outcome Measures

Name	Time	Method
recurrent myocardial ischemia	1 month

Trial Locations

Locations (1)

Newark Beth Israel Medical Center; 🇺🇸 Newark, New Jersey, United States